Business Context and Reporting Period
This Form 8-K Current Report covers events occurring on or around September 30, 2025, for Capstone Holding Corp. (Nasdaq: CAPS), a Delaware corporation. The filing primarily details a material definitive agreement involving the exchange of debt held by controlling Brookstone entities for new preferred stock, as well as a voluntary adjustment to the conversion price of existing senior secured convertible notes.
Key Financial Metrics and Capital Structure
- Debt Exchanged: The Company exchanged notes held by Brookstone entities totaling approximately $1.94 million in combined principal and interest.
- BP Peptides, LLC: $847,919.95
- Brookstone Partners Acquisition XXI Corporation: $1,089,222.22
- Preferred Stock Issuance: In exchange for the notes, the Company issued 1,467,343 shares of newly created Series Z 8% Non-Convertible Preferred Stock.
- BP Peptides received 642,276 shares.
- Brookstone Acquisition received 825,067 shares.
- Convertible Notes: The Company has outstanding senior secured convertible notes with an aggregate original principal of up to $10,909,885. The first note issued was approximately $3,272,966.
- Stock Price Reference: The exchange was valued based on a Common Stock closing price of $1.32 on September 29, 2025.
Material Changes and Agreements
Exchange Agreement (Item 1.01)
On September 30, 2025, the Company entered into an Exchange Agreement with its Brookstone lenders. The lenders agreed to exchange their notes (maturing June 30, 2026) for Series Z Preferred Stock. Key terms include:
- Dividends: 8% per annum cumulative, accruing daily on a $1.32 stated value. Payment is at the Board's option in cash or payment-in-kind (PIK) via additional Series Z shares.
- Voting Rights: One vote per share, voting as a single class with Common Stock.
- Redemption: Redeemable upon the earlier of the seven-year anniversary or a fundamental transaction.
- Authorization: Up to 3,500,000 Series Z shares are authorized.
Conversion Price Voluntary Adjustment (Item 1.01)
On October 5, 2025, the Company and an institutional investor agreed to adjust the terms of the Convertible Notes issued in July 2025:
- Price Reduction: The conversion price for the entire principal of the note was reduced to $1.00, effective October 6, 2025 (previously split between $1.00 and $1.72).
- Redemption Obligation Waiver: The Company is not obligated to redeem the notes using proceeds from Permitted ATM or Equity Line sales until April 6, 2026.
- Redemption Price: Fixed at 100% of the conversion amount being redeemed.
Guidance, Risks, and Contingencies
The filing does not provide specific financial guidance or forward-looking revenue projections. However, the following risks and contingencies are noted:
- Dilution Risk: The issuance of Series Z Preferred shares and the reduction of the conversion price on convertible notes to $1.00 may increase potential dilution to common shareholders upon conversion or dividend payments in kind.
- Liquidity Management: The deferral of redemption obligations until April 2026 provides temporary relief on cash outflows related to the convertible notes.
- Related Party Transactions: The exchange involves entities controlled by the CEO and Chairman, representing a significant related-party transaction.
Investor Verification Checklist
- Verify the full text of the Exchange Agreement (Exhibit 10.1) and Certificate of Designation (Exhibit 3.1) for specific covenants and redemption triggers.
- Confirm the impact of the 8% dividend rate on future cash flow, specifically the likelihood of Payment-in-Kind (PIK) issuance versus cash payment.
- Review the Conversion Price Voluntary Adjustment Notice (Exhibit 10.2) to understand the full scope of the price reduction on the $10.9M note facility.
- Monitor the April 6, 2026 date when the waiver on redemption obligations from equity sales proceeds expires.
- Assess the voting power of the new Series Z Preferred shares relative to existing Common Stock.